Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EUDA Health Holdings Limited (EUDAW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. EUDA files current reports on Form 6-K under the Securities Exchange Act of 1934, which furnish information about material events, financing transactions, and other matters related to its Singapore-based health technology business and Southeast Asian digital healthcare ecosystem.
In these filings, EUDA has described entering into an At The Market Offering Agreement that allows it to issue and sell ordinary shares through a sales agent, as well as a convertible promissory note purchase agreement under which notes are convertible into newly issued ordinary shares at a discount to the trading price, subject to specified conditions. The company’s 6-K reports also reference a shelf registration statement on Form F-3, with certain agreements and legal opinions incorporated by reference into that registration statement and related prospectus supplements.
Filings on this page may also include reports of press releases furnished as exhibits, such as announcements about Nasdaq listing delinquency letters tied to delayed Form 10-K and Form 10-Q filings. While those periodic reports are filed separately, the 6-K disclosures explain the listing rule framework and the company’s responses.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms in documents like Form 6-K, describe the structure of at-the-market offerings and convertible notes, and clarify how these instruments relate to EUDA’s ordinary shares and warrants. Users can review new filings as they appear on EDGAR, see how specific agreements affect EUDAW-related securities, and use AI-generated insights to navigate complex legal and financing language more efficiently.
EUDA Health Holdings Limited approved and is implementing a 1-for-20 reverse stock split of its ordinary shares, effective at market open on March 23, 2026 on the Nasdaq Capital Market. The company states that shareholder ownership percentages and voting power will remain substantially the same aside from minor rounding effects.
Shares outstanding will be reduced from approximately 50,307,491 to approximately 2,515,375, with fractional shares rounded up and no cash paid in lieu. EUDA’s outstanding warrants will be adjusted proportionately, cutting underlying shares from about 4,458,625 to about 222,932 while increasing the exercise price from $11.50 to $230.00 per share equivalent.
EUDA Health Holdings Ltd Chief Financial Officer Tay Whye Shin has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. The filing establishes this officer’s reporting status under SEC rules but does not report any stock transactions.
EUDA Health Holdings Ltd director Liew Kwong Yeow filed an initial ownership report showing direct holdings of 3,000 Ordinary Shares. This Form 3 does not report any recent buy or sell transactions; it simply establishes his current equity stake in the company.
EUDA Health Holdings Ltd director Lew Chern Yong has filed a Form 3, which records his status as an insider of the company. The provided data does not list any equity transactions or derivative positions, and the transaction summary shows no buys, sells, or other reportable trades.
EUDA Health Holdings Ltd director Huang Bo filed an initial statement of beneficial ownership as a new insider. This Form 3 filing does not report any share purchases, sales, or other transactions, and instead serves to formally register Huang Bo’s status as a reporting person for EUDA Health.
EUDA Health Holdings Limited completed a registered offering of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000, using its Form F-3 shelf registration and a March 2026 prospectus supplement. The company plans to use the net proceeds for general corporate purposes, including possible acquisitions, business expansion and working capital.
Separately, EUDA repurchased in full a previously issued warrant that was exercisable for 2,000,000 newly issued ordinary shares, paying $125,000 on February 27, 2026, and the warrant was cancelled. The report also incorporates this information by reference into the company’s existing Form F-3 registration statement.
EUDA Health is registering 12,500,000 ordinary shares in a registered direct offering. The offering is being made pursuant to Securities Purchase Agreements dated February 24 and 25, 2026 and is being issued directly to accredited investors without a placement agent.
The company estimates net proceeds of approximately $3,692,000. As of the date of this Prospectus Supplement there were 37,807,491 Ordinary Shares outstanding; the company states there will be 50,307,491 Ordinary Shares issued and outstanding after this offering. The Ordinary Shares trade on Nasdaq under the symbol EUDA; the cited closing price on February 27, 2026 was $0.9747.
EUDA Health Holdings Limited has filed a 2026 prospectus supplement for its existing at-the-market equity program, allowing it to sell ordinary shares with an aggregate offering price of up to $10,000,000 through Chardan Capital Markets as sales agent. The company states that no ordinary shares have been sold under this Sales Agreement to date.
The supplement highlights business risks, including uncertainty around plans to work with third parties to establish a longevity clinic in Shenzhen, China, for which no binding agreements or approvals currently exist. It also notes uncertainty around launching an integrated digital health and rewards platform and the future use of QB coin utility cryptocurrency, which is still in development by a third party. EUDA cautions that failure of these initiatives could materially and adversely affect its business and results of operations.
EUDA Health Holdings Ltd amended its annual report describing continued operating losses, a May 8, 2024 acquisition of CK Health Plus Sdn Bhd and significant non-cash impairment charges. The Company reported 37,153,049 ordinary shares outstanding as of December 31, 2024 and recorded a $14,755,560 impairment of intangible assets in 2024.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern within one year, noting recurring losses since 2020, cash of approximately $0.2 million and a need to raise additional financing. The CK Health acquisition was settled with 8,571,428 newly issued shares valued at $15.0 million (at $1.75 per share), plus a contingent 1,000,000-share earnout tied to 2024–2025 net income milestones.
EUDA Health Holdings Limited reports a new agreement with its institutional investor around an existing convertible note. The investor originally agreed to purchase up to $10,000,000 in convertible promissory notes and had already bought a $1,000,000 note that converts into ordinary shares at an 85% discount each time it converts. The company now has delivered 41,620 ordinary shares at a conversion price of $0.901 per share and both parties have mutually waived past breaches of the note and related agreement. In return, the investor agreed not to make further conversions until December 15, 2025, unless EUDA’s Nasdaq closing price reaches $2.00 or higher for three consecutive trading days. EUDA also states it does not intend to purchase any additional notes under the note purchase agreement.